Medtronic and the Therapeutic Goods Administration have issued an Urgent Product Correction for a MiniMed Mobile App Android software version 3.2.0.

Medtronic has identified a problem where the app disconnects from the pump.

Users of MiniMed Mobile App Android 3.2.0 should update to version 3.2.1 or higher as soon as possible to resolve this problem.

Please click on the following link to download the new version of the app.

To confirm the latest app version on your Android device, follow these steps:

• Open the Google Play Store app.
• Tap Menu and then Manage apps & devices.
• Apps with an update available are labelled “Update available.” You can also search for a specific app.
• Tap Update.

If you have further questions or need assistance, please call the Medtronic 24-Hour Technical Support line at 1800 777 808.

The first new therapy for type 1 diabetes in nearly a century, which works to delay the need for insulin therapy in type 1 diabetes, has been approved for use in Australia by the Therapeutic Goods Administration. 

Tzield (teplizumab) works to preserve beta cell and insulin production, delaying the autoimmune mechanism that drives type 1 diabetes, and could see thousands of Australians able to delay insulin therapy for an average of two years. 

It’s the result of nearly forty years’ of career-defining research from a dedicated team of researchers, and represents a major development for people aged 8+ and living with stage 2, type 1 diabetes.  

The therapy’s arrival in Australia represents a game-changing shift in treatment and management made possible through long-term funding support for critical research. 

Preserving beta cells and insulin, alongside understanding the autoimmune system mechanism, has long been a major goal of diabetes research globally. With this new listing, Australians will have access to cutting-edge medicine that will help thousands of Australians delay insulin therapy. 

Australian Diabetes Alliance member Breakthrough T1D have supported the research that led to this therapy since its inception in the late 1980s, funding a dedicated team of researchers for nearly forty years. 

Tzield will now be available for people living with stage 2 type 1 diabetes, however is not listed on the Pharmaceutical Benefits Scheme (PBS).  

More than 145,000 Australians live with type 1 diabetes, with a further 25,000 estimated to be living with early-stage or undiagnosed type 1 diabetes.  

Type 1 diabetes is an auto-immune condition where the body’s own immune system destroys the beta cells in the pancreas which produce insulin.  

We don’t yet know the cause and currently there is no cure.   

Insulet has issued a critical recall affecting specific lots of Omnipod 5 and Omnipod DASH Pods after identifying a manufacturing issue through routine product monitoring.

The issue relates to a small tear that may occur in the Pod’s cannula (tubing), just above the skin. If this happens, insulin may leak outside the Pod instead of being fully delivered into the body, which can result in less insulin being delivered than intended.

People using an affected Pod may notice signs such as moisture on the skin or Pod adhesive, or the smell of insulin. However, in some cases, the leak may not be obvious. This means blood glucose levels may rise and may not respond as expected to insulin delivery. While users of Omnipod 5 in Automated Mode may receive an alert, this issue can also occur without any notification, so it’s important not to rely solely on Pod alerts.

Affected lots include:

• Omnipod^Âź 5: PH1U10212421
• Omnipod DASH^Âź: PD1U09042421, PD1U11122421, PD1U11202421

Reduced insulin delivery can lead to high blood glucose levels (hyperglycaemia). In more serious cases, prolonged high blood glucose can lead to diabetic ketoacidosis (DKA), a life-threatening condition that requires urgent medical treatment. Globally, there have been 24 reports of serious adverse events, including hospitalisation and DKA. There have been no reported deaths and no serious adverse events reported in Australia.

This issue does not affect continuous glucose monitoring (CGM) systems or CGM readings.

Insulet has identified the cause of the problem and implemented corrective actions. Pods that are not included in the affected lots remain safe to use, and supply is not expected to be disrupted.

Impacted customers are being contacted directly with instructions on how to check lot numbers, stop using affected Pods, and arrange free replacements. If you think your Pods may be affected, stop using them immediately and switch to a Pod from an unaffected lot.

For support, contact Insulet Product Support on 1800 954 074 (available 24/7), or speak with your healthcare professional.

is a time for Australians to reflect on our shared history and to recommit to building respectful relationships with Aboriginal and Torres Strait Islander peoples. This year’s theme, “All In”, is a call for every Australian to take meaningful action towards reconciliation and to recognise that lasting change requires a collective effort.

For șÚÁÏÍű, reconciliation is central to improving health outcomes and addressing inequities faced by Aboriginal and Torres Strait Islander communities. This week is not only a moment for reflection, but also a reminder of the ongoing responsibility to listen, learn and act in partnership.

The need for action is clear. Aboriginal and Torres Strait Islander communities are experiencing the world’s highest rates of youth onset type 2 diabetes. The prevalence of type 2 diabetes among young people aged 15 to 24 has doubled between 2019 and 2024. Overall, Aboriginal and Torres Strait Islander people are also almost four times more likely than non Indigenous Australians to live with diabetes or pre diabetes. These disparities are reflected across the health system, with diagnosis rates around three times higher and hospitalisation rates up to five times higher than for non-Indigenous Australians.

Addressing these inequities cannot occur in isolation from reconciliation. șÚÁÏÍű acknowledges Aboriginal and Torres Strait Islander peoples as the Traditional Custodians of this country and recognises that improving health outcomes requires long term partnerships and culturally safe care. Reconciliation provides the framework for this work, ensuring that solutions are shaped with, and led by, communities.

A key step in this journey is șÚÁÏÍű’s Reflect Reconciliation Action Plan (RAP), which sets the foundation for and embeds reconciliation across the organisation’s work and culture.

RAPs are designed to create practical and measurable change, and today more than 5.9 million Australians work or study in organisations with a RAP, demonstrating the growing national commitment to reconciliation.

șÚÁÏÍű’s Reflect RAP focuses on building organisational capability, strengthening partnerships and embedding accountability. That includes integrating reconciliation goals into business planning, improving reporting and tracking of Aboriginal and Torres Strait Islander representation within the workforce and membership, and developing policies that support equity and inclusion.

Building cultural capability is also a key focus. Staff education, recognition of NAIDOC Week, Coming of the Light, Sorry Day and Close the Gap Day, as well as ongoing engagement with Aboriginal and Torres Strait Islander organisations and leaders are helping to deepen understanding and strengthen respectful partnerships.

Membership with Reconciliation QLD and Reconciliation NSW is another important step, enabling șÚÁÏÍű to collaborate, learn and take practical action alongside others committed to reconciliation. These partnerships help ensure that efforts are informed, respectful and responsive to community needs.

Following the successful implementation of its Reflect RAP, șÚÁÏÍű is now progressing towards an Innovate RAP, which will focus on practical long term actions to improve health outcomes for Aboriginal and Torres Strait Islander peoples. This next stage reflects a deepening commitment to reconciliation as an ongoing process, one that requires sustained action, accountability and collaboration.

Reconciliation is not achieved through a single initiative or moment in time. It happens person by person, community by community, through sustained, collaborative effort. National Reconciliation Week runs from 27 May to 3 June each year, marking significant milestones in Australia’s history including the and the .

The 2026 theme, “All In”, reminds us that reconciliation must live in the hearts, minds and actions of all Australians if we are to move forward together. Reconciliation will not happen by itself, and it will not happen without all of us.

The Therapeutic Goods Administration has issued a notice that AA-Med Pty Ltd is recalling two lots of Dexcom G7 sensors.

The lots affected are 1725204004 and 1725069002.

These lots were identified for disposal and destruction in the USA due to incomplete sterilisation and deployment failure during testing. The devices from both lots were stolen during the disposal process, and sold to third parties via unauthorised supply channels.

As the supply channels for these lots cannot be established, the risk of some devices reaching the Australian market cannot be excluded.

No Dexcom G7 sensors received through the NDSS will be impacted by the recall.

The TGA advised that if you have any of the affected products, immediately discontinue use and dispose of them. 

For more information, please refer to the market action .

New data from self-serve health check stations reveals as many as one in three Queenslanders could have risk factors that they should discuss with their health professional. 

The data reinforces the need for greater access to early screening, an area that’s being addressed through a pilot partnership between șÚÁÏÍű, Target Australia, and SiSU Health, that could help people catch their risk of chronic conditions sooner. 

The data also highlights the need for preventative screening that’s accessible and affordable, and reduces stigma for consumers. 

Some of the risk factors identified included high blood pressure, very high body mass index (BMI, greater than 35), and type 2 diabetes risk, as measured by AUSDRISK criteria. 

The findings also highlight the significant potential of preventative screening to reduce complications, benefiting individuals and easing pressure on the health system.  

Health check stations are self-serve TGA-registered medical devices that can provide validated screening results in minutes, which can give baseline health data which supports conversations with health professionals. 

Thanks to the partnership, health check stations have been available in selected Target stores in South Australia for 4 weeks and so far almost 5,000 people have undergone a health check. 

The partnership now has 10 stations available across selected Target stores in Queensland, allowing shoppers to check things like blood pressure, heart rate, height, weight, body composition, and risk of developing type 2 diabetes (against AUSDRISK criteria), all discreetly delivered directly by secure app.  

Currently, almost 260,000 Queenslanders live with type 2 diabetes, with a further 102,500 estimated to be living with undiagnosed type 2 diabetes. Nationally, 2 million Australians are living with all types of diabetes.  

șÚÁÏÍű’s Group CEO Justine Cain said the initiative was an important step forward in exploring new ways to make preventive health more accessible to the community.  

“These early numbers strongly suggest that we’re taking the right steps in getting preventative healthcare out into the community. It’s never too early or too late to take your health seriously,” Ms Cain said.  

“We know that delivering an easy-to-access, stigma free health check could be all that someone needs to get life-changing health data. 

“A five-minute health check could be the best thing you put in your shopping basket today. 

“Millions of Australians are either living with or at risk of type 2 diabetes, and many don’t realise it.  By partnering with a trusted brand like Target, we have a powerful opportunity to reach people earlier. Early detection is one of the most powerful tools we have to help people take control of their health.” 

Ms Cain said the partnership with Target reflects șÚÁÏÍű’s commitment to innovative approaches to prevention.  

“These health stations at Target stores provide a simple way for people to learn their risk, track their results, and, if needed, seek support early through their GP or health professional. Small steps like this can make a big difference.” 

Target will host the health stations in 10 participating Queensland stores, in addition to the 10 already-deployed locations in South Australia, as part of the pilot, providing customers with a convenient five-minute check while they shop.  

Kmart Group (Kmart and Target) Chief Corporate Affairs & Sustainability Officer Alexandra Staley said Target is proud to partner with șÚÁÏÍű to bring accessible health solutions into everyday retail environments.  

“At Target, we’re committed to supporting our local communities. By hosting these health stations in our stores, we’re helping make it easier for customers to access simple, free health checks as part of their everyday routines.”  

“This pilot reflects our broader focus on creating positive community impact — using our national store network to help explore ways to remove barriers to early detection and support better health outcomes for Australians.”  

The health checks have already proven successful in other settings, with thousands of Australians using health stations each year to proactively monitor their health.  

Machines are now available in Target stores across Queensland. Participating stores include: Bundaberg, Carindale, Strathpine, Rockhampton, Morayfield, Ipswich, Browns Plains, Mt Gravatt, Mt Ommaney, Runaway Bay. 

The diabetes sector has welcomed the Federal Government’s response to the Parliamentary Inquiry into Diabetes, which provides in-principle support for a number of key recommendations needed to arrest Australia’s diabetes epidemic.

The sector is encouraged by the government’s willingness to increase awareness about diabetes, improve diabetes care, expand access to GLP-1 medicines and grow diabetes research investments.

șÚÁÏÍű’s Group CEO Justine Cain said the government’s response shows it has heard the strong advocacy from the diabetes sector.

“șÚÁÏÍű, as the national peak body for all Australians living with diabetes, will continue to relentlessly pursue avenues to increase support for the diabetes community alongside the whole sector,” Ms Cain said.

“There was a comprehensive package of measures recommended in the Inquiry’s report, and the government’s response to them is an important step forward.

“In particular, we welcome support for public health campaigns to increase awareness of the early signs of all types of diabetes as well as prevention measures; an increase in MBS item numbers for diabetes educators; expanding eligibility for GLP-1 medicines; and the funding and coordination of diabetes research.”  

Ms Cain said the sector understands that the challenging economic circumstances facing Australia at this time meant some recommendations had been noted, but that ongoing advocacy would continue.

“We look forward to working with government as we continue to find a way to make insulin pumps and continuous glucose monitors more affordable for people living with diabetes whose lives would be drastically improved by these technologies,” Ms Cain said.

“In this week’s Federal Budget, the government announced funding for important initiatives that will support the diabetes community including investments in research, the pharmaceutical benefits scheme, and My Health Record. We welcome this funding which will deliver practical support.

“Equity of access to technologies continues to be a critical focus and we must work together with government to find a way to make this standard care affordable for Australians. Health equity is critical. In a cost of living crisis, access to diabetes technology and services is more important than ever,” Ms Cain said.

Australian Diabetes Educators Association CEO Melanie Morris said “we welcome the government’s response and the support in principle for a number of key recommendations that will improve access to care, strengthen the diabetes workforce, and enhance prevention.

“Importantly, this includes support to improve access to Credentialled Diabetes Educators (CDEs), including in high‑risk outer metropolitan, rural and remote communities, as well as expanding MBS‑subsidised allied health services and access to longer consultations,” Ms Morris said.

Australian Diabetes Society CEO Sof Andrikopoulos said there were a number of encouraging signs for diabetes research.

“When taken together, the announcement in the Federal Budget that MRFF funding will be increased to $1 billion by 2030, and the in-principle support for the diabetes research recommendation for the inquiry, we can see promising roads ahead for Australia’s diabetes community,” Mr Andrikopoulos said.

Dr Matthew Hare, President of the Australasian Diabetes in Pregnancy Society noted new initiatives in the Federal budget that will enhance opportunities for women living with diabetes to have the best health outcomes for them and their children, such as improved access to long-acting reversible contraception.

“We are committed to continuing to work with the Australian Government to ensure equitable access to life-changing technologies for women with diabetes that will improve health outcomes across generations,” Dr Hare said.

Twenty-three key recommendations were included in a comprehensive report tabled in 2024 by the Health, Aged Care and Sport Committee following its landmark .

The diabetes community will continue to work with government on increasing affordable access to diabetes technologies including insulin pumps and continuous glucose monitors.

“These technologies aren’t a ‘nice to have’, they are absolutely necessary,” Ms Cain said.

“Right now, we’re seeing a widening gap between what we know works and what people can afford. Cost should never determine whether someone can access life‑changing care.

“We very much look forward to continuing the discussions with government on how we can make this a reality,” Ms Cain said.

New research supported by șÚÁÏÍű has confirmed that a person’s genes can influence how well widely used diabetes medicines such as Mounjaro and Ozempic work.

The discovery could pave the way for more personalised prescribing in the future, with treatments tailored to a person’s genetic profile to improve outcomes.

The findings come from an international team including researchers at Adelaide University and were published in the international journal .

The research was led by South Australian endocrinologist and clinician researcher Dr Mahesh Umapathysivam (Adelaide University), Dr Alraldi (ETH Zurich), Professor Gloyn (Stanford University) and Prof Stoffel (ETH Zurich), and was supported in Adelaide by funding from the șÚÁÏÍű Research Program in 2024.

Dr Umapathysivam said the team investigated how genetic differences affect responses to medicines known as GLP-1 receptor agonists, a class of drugs that help lower blood glucose levels and can also assist with weight loss.

“Our studies suggest that a person’s genetic profile may influence how well these medicines slow the emptying of the stomach after eating,” Dr Umapathysivam said.

“This process is important because slower stomach emptying contributes to the medicines’ effect on blood glucose levels.”

The research studied the effect of genetic variants which alter the activity of a protein called PAM. Approximately 10% of the population carry a loss-of-function variant in the PAM gene and have lower PAM activity and higher levels of GLP-1 after meals, but without the expected improvement in the body’s ability to lower blood glucose after a meal, something known as the “incretin” response.

“As a result, these individuals showed a reduced response to GLP-1 receptor agonist medicines,” Dr Umapathysivam said.

“Our findings suggest that people who carry these variants may have a form of GLP-1 resistance, meaning the medicines may not work as effectively for them.”

The team also observed similar patterns in mouse studies, strengthening the evidence that genetic differences can influence how patients respond to this class of medicines.

The discovery could help guide future precision medicine approaches, allowing doctors to better predict who is likely to benefit from these treatments and who may need alternative therapies.

Adelaide’s Laverne Naicker, who was diagnosed with type 2 diabetes about 20 years ago, said she thought it was a shame when Ozempic didn’t work for her.

“I was pretty disappointed,” Laverne said. “It was a big deal. Ozempic seemed to work like a miracle for other people, so why not me?

“For every medication there are side effects. For me, I experienced burping, abdominal discomfort like pinching, and terrible headaches.

“There was no flip side. Ozempic didn’t help with my diabetes. This research is awesome because it has the potential for people like me not to waste time, hope, and feeling unwell if the medication isn’t going to work.”

Laverne has since started insulin to help manage her glucose levels.

șÚÁÏÍű’s Group CEO Justine Cain said the results highlighted the importance of sustained investment in diabetes research.

“șÚÁÏÍű is proud to have supported this groundbreaking project,” Ms Cain said.

“Research is the key to changing the future of diabetes.

“Innovative studies like this show how Australian researchers are helping lead the world in understanding diabetes, how to prevent it, and how to improve treatment for people living with the condition.”

șÚÁÏÍű Group Executive, Health, Economics & Research, Amber Willink, said Dr Umapathysivam’s team’s research supports treatments being used where they will have the greatest benefit.

“Personalised medicine is not a future concept. It’s emerging now. This research shows how genetic insights can help ensure the right treatment reaches the right person at the right time.”

Researchers from the University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Newcastle University, University of Bath and University of Exeter also contributed to the work. 

Established almost 40 years ago, the șÚÁÏÍű Research Program supports outstanding research across prevention, treatment and the search for a cure for all types of diabetes.

The program also helps develop the next generation of diabetes researchers and relies on the generosity of donors to continue supporting world-class research in Australia.

More information about the șÚÁÏÍű Research Program and how to support its work is available at the șÚÁÏÍű website. Find out more about how to support us.

People using YpsoPump Orbit Micro 2.0 infusion sets are being advised of a product update designed to improve comfort and reduce the likelihood of skin irritation. 

The update applies to YpsoPump Orbit Micro 2.0 infusion sets supplied in Australia since October 2023. The products are not being recalled and remain safe to use. 

The change follows routine post-market monitoring, which identified a higher frequency of reported skin irritation among some users. Skin irritation is recognised as a possible reaction when using infusion sets, and guidance recommended rotating infusion sites or considering alternative sets if irritation occurs. 

A detailed review found that the design of the Orbit Micro 2.0 infusion set base and its welding structure could create a slightly rough surface where the device contacts the skin. Over time, and with the need to replace the base every 48 hours, this may contribute to mechanical irritation of the skin. 

In response, the manufacturer, mylife Diabetes Care Australia, has updated the design and production process to create a smoother skin-contact surface. Testing has shown this refinement significantly reduces mechanically induced skin irritation, without changing the materials used in the product. 

The updated infusion sets are now being introduced through normal pharmacy and wholesale supply channels in Australia. No action is required for people currently using the device. 

Those using mylife Loop systems that rely on Orbit Micro 2.0 infusion sets should simply be aware of the update as new stock becomes available.  

Individuals who have experienced skin irritation with earlier versions may wish to speak with their healthcare team or contact mylife Diabetes Care Australia customer support on 1800 447 042 to access the updated product. 

The Urgent Product Correction information has been published on the TGA website:  

Shoppers at selected Target stores in South Australia can now take five from checking out the latest fashion fits to check in on their health, thanks to a pilot partnership between the retailer, șÚÁÏÍű, and SiSU Health.  

The partnership will see 10 SiSU Health Check stations deployed across selected Target stores in South Australia, where shoppers can check a range of health markers such as blood pressure, heart rate, height, weight, body composition, and risk of developing type 2 diabetes (against AUSDRISK criteria), all discreetly delivered directly by secure app.  

Health Check stations are self-serve TGA-registered medical devices that can provide validated screening results in minutes, which can give baseline health data and support conversations with health professionals.   

The initiative aims to encourage early screening for a range of common health markers that could help people catch their risk of chronic conditions sooner.  

Currently, just over 121,000 South Australians live with all types of diabetes, with a further 34,000 estimated to be living with undiagnosed type 2 diabetes. Nationally, 2 million Australians are living with diabetes.  

Diabetes Australia’s Group CEO Justine Cain said the initiative was an important step forward in exploring new ways to make preventive health more accessible to the community.  

“With this partnership there’s no need for people to ‘shop around’ for good health – now they can check their risk while at Target checking the latest fashion,” Ms Cain said.   

“A five-minute health check could be the best thing you put in your shopping basket today. 

“Millions of Australians are either living with or at risk of type 2 diabetes, and many don’t realise it.  By partnering with a trusted brand like Target, we have a powerful opportunity to reach people earlier. Early detection is one of the most powerful tools we have to help people take control of their health.” 

Ms Cain said the partnership reflects șÚÁÏÍű’s commitment to innovative approaches to prevention.  

“We know that when health checks are easy, accessible and stigma free, more people engage. These health stations at Target stores provide a simple way for people to learn their risk, track their results, and, if needed, seek support early through their GP or health professional. Small steps like this can make a big difference.” 

Target will host the health stations in 10 participating stores, as part of the pilot, providing customers with a convenient five-minute check while they shop.  

Kmart Group (Kmart and Target) Chief Corporate Affairs & Sustainability Officer Alexandra Staley said Target is proud to partner with șÚÁÏÍű to bring accessible health solutions into everyday retail environments.  

“At Target, we’re committed to supporting our local communities. By hosting these health stations in our stores, we’re helping make it easier for customers to access simple, free health checks as part of their everyday routines.”  

“This pilot reflects our broader focus on creating positive community impact — using our national store network to help explore ways to remove barriers to early detection and support better health outcomes for Australians.”  

The health checks have already proven successful in other settings, with thousands of Australians using SiSU Health Stations each year to proactively monitor their health.  

SiSU Health Check machines are available now in Target Australia locations across South Australia. Participating stores include: Centrepoint (Adelaide CBD), Sefton Park, Edwardstown, Newton, Marion, Tea Tree Plaza, West Lakes, Hollywood Plaza, Elizabeth, Reynella.